Impact of CD34+ Cell Dose on Outcomes in Haploidentical Peripheral Blood Stem Cell Transplantation in Acute Leukemia

Strategic Insights -

Researchers at Yonsei University College of Medicine in Seoul, South Korea, have published a study on the impact of CD34+ cell dose on outcomes in haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) in acute leukemia. The study, which was conducted between 2010 and 2020, involved 81 patients with acute leukemia who underwent haplo-PBSCT with reduced-intensity conditioning. The results of the study suggest that graft cell dose should be carefully balanced to optimize outcomes in haplo-PBSCT.

Key Takeaways:

  • The study found that allogeneic hematopoietic stem cell transplantation remains a curative option for acute leukemia.
  • An adequate CD34 cell dose is essential for engraftment, but the optimal upper threshold in haplo-PBSCT remains unclear.
  • The study retrospectively analyzed 81 patients with acute leukemia who underwent haplo-PBSCT with reduced-intensity conditioning between 2010 and 2020.
  • Patients were stratified by CD34 cell dose, and the results showed that graft cell dose should be carefully balanced to optimize outcomes in haplo-PBSCT.
  • The study suggests that higher CD34 cell doses are associated with improved outcomes, but the optimal dose is unclear.
  • The study was conducted at Yonsei University College of Medicine in Seoul, South Korea, and was supported by financial aid from Yonsei University College of Medicine.
  • The study highlights the importance of careful balancing of graft cell dose to optimize outcomes in haplo-PBSCT.

Statistics:

  • 81 patients with acute leukemia underwent haplo-PBSCT with reduced-intensity conditioning between 2010 and 2020.
  • Patients were stratified by CD34 cell dose, resulting in three groups: 5.5 × 10^5 cells/kg.
  • The study found that graft cell dose was significantly correlated with overall survival (OS) and disease-free survival (DFS).
  • Patients with higher CD34 cell doses had improved OS and DFS rates compared to those with lower CD34 cell doses.
  • The median OS and DFS rates were 456±167 days and 341±140 days, respectively.

Sources:

  • NewsRx. Study Results from Yonsei University College of Medicine Provide New Insights into Graft-Versus-Host Disease (Impact of CD34+ cell dose on outcomes of haploidentical peripheral blood stem cell transplantation in acute leukemia). Hematology Week. August 25, 2025; p 2541.
  • Blood Research. Impact of CD34+ cell dose on outcomes of haploidentical peripheral blood stem cell transplantation in acute leukemia. 2025;60(1):42.